ELI LILLY & CO

Discover how Eli Lilly’s new obesity drugs—retatrutide, Foundayo, and Zepbound—show Phase 3 promise for weight loss, diabetes and sleep apnea, reshaping the market.

Explore how Eli Lilly’s 50% cut to its Alzey plant and the $1.9 B partnership with Ascidian Therapeutics reshape its strategy, boost portfolio diversity, and secure long‑term growth.

Explore Eli Lilly’s latest shareholder moves, breakthrough obesity and oncology trials, and strategic bond issuance that strengthen its market position and future growth.

Explore how Eli Lilly’s breakthrough obesity drug retatrutide and its expanding oncology lineup, set to debut at ASCO 2026, are positioning the company for long‑term growth and investor confidence.

Read how Eli Lilly’s 2026 earnings forecast, Zepbound/Foundayo gains, and a $2.25 B gene‑editing partnership could boost investor confidence amid GLP‑1 competition.

Eli Lilly’s Q1 earnings will reveal if Foundayo’s slow GLP‑1 adoption and its $7 billion Kelonia CAR‑T deal can sustain growth and diversify revenue in 2024.

Explore how Eli Lilly’s weight‑loss drugs navigate the CMS “bridge program” and delayed BALANCE pilot, plus EMA procurement trends, to secure Medicare revenue and long‑term growth.

Discover how Eli Lilly’s acquisition of Kelonia’s universal CAR‑T platform and launch of the oral GLP‑1 drug Foundayo combine oncology innovation with obesity treatment, driving growth and shareholder value.

AI‑driven Lilly‑Insilico deal promises faster, safer oral drugs & Phase 3b Taltz‑Zepbound hits psoriasis and metabolic targets, boosting Lilly’s therapeutic edge.

How Eli Lilly’s AI‑driven drug‑development boosts speed and investor appeal while keeping a steady, low‑volatility stock profile.